Topical diacerein in plaque psoriasis (adult) explores if a cream helps skin improve
Official title: The Efficacy of Topical Diacerein Cream in Patients With Psoriasis Vulgaris
Run by Cairo University · NCT07352306 · Data updated 2026-11-12
This trial tests whether applying a topical diacerein cream twice daily for 8 weeks helps adults with mild-to-moderate psoriasis vulgaris improve symptoms more than a placebo.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | April 11, 2026 |
| Main results expected | February 1, 2027 |
| Study ends | May 1, 2027 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT07352306 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with mild-to-moderate plaque psoriasis (BSA <10%, PASI <10 and/or DLQI <10) who have not recently used systemic or topical anti-psoriasis therapies as specified.
✕Probably not a fit
Patients with more extensive disease, pustular psoriasis, psoriatic arthritis, or those who do not respond to topical diacerein may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a phase IV, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a 1% topical diacerein cream in adults with psoriasis vulgaris. Participants are assigned to receive either the active cream or matching placebo for two months, with follow-up visits through Week 8 and an additional assessment after stopping treatment. The primary endpoint is the proportion achieving PASI-75 at Week 8. Secondary endpoints include other PASI responses, global assessments, patient-reported outcomes, and safety measures. Eligible participants are adults with mild disease by body surface area and PASI/quality-of-life scores, without recent systemic or topical anti-psoriasis therapies or certain exclusions such as pustular psoriasis or psoriatic arthritis.
Why it matters
Potential benefit: If successful, participants may experience clearer skin and improved quality of life, along with a potential new topical option for psoriasis management.
How similar studies have gone: Prior topical IL-1β–inhibitor approaches have shown potential signals in skin inflammatory conditions, but this diacerein formulation for plaque psoriasis is a relatively novel application with limited precedent.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years old of both genders. * Patients with mild chronic plaque psoriasis body surface area (BSA \< 10%) along with Psoriasis Area and Severity Index (PASI) score of \< 10, and/or Dermatology Life Quality Index (DLQI) score of \<10. Exclusion Criteria: * Documented hypersensitivity or idiosyncratic reaction to the investigational product or any excipients contained within the cream formulation. * Intake of anti-psoriatic systemic therapy within the last 3 months, or topical treatments within the last 2 weeks. * Patients with pustular psoriasis. * Pregnant and breast-feeding individuals. * Patients with psoriatic arthritis.
Where it's running
-
Kasr Al-Ainy Psoriasis Unit
Cairo, Egypt Recruiting
Study contacts
- Study coordinator: Alaa A Helal, BSc in Pharmacy
- Email: alaa.ashraf.muhammad@std.pharma.cu.edu.eg
- Phone: 1124438381
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HRS-4139 safety and pharmacology in healthy adults
This early-phase study tests a single dose of HRS-4139 to see if it is safe and how the body handles it in healthy adults aged 18–55.
-
Total Coumarin botanical cream for psoriasis vulgaris
This trial will try a botanical Total Coumarin cream applied twice daily for 8 weeks to see if it helps adults with mild to moderate psoriasis.
-
Vaspin gene changes and blood vaspin levels in people with psoriasis
This test will see if specific vaspin gene variants are linked to blood vaspin levels in people with psoriasis.
-
Optimizing biologic dosing for psoriasis treatment
This study is testing if a new way of adjusting psoriasis medication based on blood tests can work just as well as the usual method over 18 months.
-
Treatment of psoriasis with deucravacitinib
This study is testing how well a new medication called deucravacitinib can change immune cell behavior in people with moderate to severe psoriasis.
-
Shuiniujiao Dihuang Decoction With Variation for Psoriasis
A 12-week study tests whether the Chinese medicine formula Shuiniujiao Dihuang Decoction with Variation can help people with mild to moderate plaque psoriasis compared with placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.